Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Gastric bypass, sleeve gastrectomy, gastric banding: mostly patients under 65. Main billing specialty: general surgery.
Medicare fee-for-service bariatric surgery cases in the 26 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (98 state-years, 2020–2024): read it as a direction with a margin.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 0 | 508−19%/yr | −19%/yr | 0.21.3× | 0% | 360 in 2030−5.5%/yr |
| California | 3 | 481−12%/yr | −12%/yr | 0.10.8× | 0% | 400 in 2030−3.2%/yr |
| Florida | 1 | 424−17%/yr | −17%/yr | 0.21.0× | 0% | 320 in 2030−4.6%/yr |
| New York | 0 | 318−18%/yr | −18%/yr | 0.20.9× | 0% | 200 in 2030−7.2%/yr |
| Illinois | 0 | 277−14%/yr | −14%/yr | 0.21.1× | 0% | 160 in 2030−9.1%/yr |
| Massachusetts | 0 | 230−14%/yr | −14%/yr | 0.21.3× | 0% | 190 in 2030−2.8%/yr |
| Missouri | 2 | 199−20%/yr | −20%/yr | 0.31.7× | 0% | 170 in 2030−2.4%/yr |
| Ohio | 0 | 199−17%/yr | −17%/yr | 0.21.0× | 0% | 130 in 2030−6.9%/yr |
| Pennsylvania | 0 | 197−22%/yr | −22%/yr | 0.10.8× | 0% | 190 in 2030−0.9%/yr |
| New Jersey | 0 | 168−20%/yr | −20%/yr | 0.20.9× | 0% | 120 in 2030−5%/yr |
| North Carolina | 0 | 167−18%/yr | −18%/yr | 0.20.9× | 0% | 80 in 2030−11%/yr |
| Michigan | 0 | 161−24%/yr | −24%/yr | 0.21.0× | 0% | 130 in 2030−3.5%/yr |
| Virginia | 0 | 144−13%/yr | −13%/yr | 0.10.7× | 0% | 150 in 2030+0.3%/yr |
| Georgia | 0 | 137−22%/yr | −22%/yr | 0.20.9× | 0% | 120 in 2030−2.7%/yr |
| Wisconsin | 3 | 135−2.7%/yr | −2.7%/yr | 0.21.3× | 0% | 100 in 2030−4.4%/yr |
| Tennessee | 0 | 120−19%/yr | −19%/yr | 0.20.9× | 0% | 190 in 2030+8%/yr |
| Arkansas | 2 | 119−15%/yr | −15%/yr | 0.31.7× | 0% | 70 in 2030−8.4%/yr |
| Maryland | 1 | 118−17%/yr | −17%/yr | 0.10.7× | 0% | 30 in 2030−20%/yr |
| Oregon | 0 | 117−11%/yr | −11%/yr | 0.31.5× | 0% | 100 in 2030−2.1%/yr |
| Arizona | 0 | 111−16%/yr | −16%/yr | 0.10.8× | 0% | 120 in 2030+0.7%/yr |
| Indiana | 0 | 105−16%/yr | −16%/yr | 0.10.8× | 0% | 90 in 2030−1.8%/yr |
| Kansas | 1 | 105−14%/yr | −14%/yr | 0.31.4× | 0% | 60 in 2030−7.8%/yr |
| South Carolina | 1 | 105−19%/yr | −19%/yr | 0.10.8× | 0% | 70 in 2030−5.7%/yr |
| New Hampshire | 0 | 103−3.3%/yr | −3.3%/yr | 0.42.5× | 0% | 90 in 2030−2.3%/yr |
| Kentucky | 1 | 103−21%/yr | −21%/yr | 0.21.2× | 0% | 80 in 2030−5.1%/yr |
| Washington | 0 | 101−19%/yr | −19%/yr | 0.10.7× | 0% | 20 in 2030−23%/yr |
Professional codes (what the surgeon bills): CPT 43644, 43775, 43770; the hospital bills MS-DRG 619, 620, 621.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 81 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 26 companies. The most active:
Product codes: GAG (stapler, surgical), GDW (staple, implantable). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Hernia repair | 2,306 | 187,629−3%/yr | −3%/yr | 210,200 in 2030+1.9%/yr |
| Cholecystectomy & appendectomy | 2,560 | 131,995−5.4%/yr | −5.4%/yr | 140,500 in 2030+1%/yr |
| Colorectal resection | 232 | 52,254−5.2%/yr | −5.2%/yr | 53,600 in 2030+0.4%/yr |
| Antireflux & hiatal hernia surgery | 375 | 23,396−1.8%/yr | −1.8%/yr | 28,800 in 2030+3.5%/yr |
| Breast reconstruction | 66 | 13,660−6.4%/yr | −6.4%/yr | 17,400 in 2030+4.1%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 7 companies reported engagement with surgeons in the covered states worth $1.5M in consulting, speaking, meals and travel tied to these products, about $102K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.